IN THE CLAIMS:

1. (currently amended) A liposome to which a polyalkylene glycol and a genetically recombined wild type human serum albumin are bonded and which contains a pharmaceutically active ingredient.

2 - 3. (canceled)

4. (currently amended) The liposome according to ~~claim 3~~, claim 1 wherein the pharmaceutically active ingredient is an antitumor agent.

5. (currently amended) A pharmaceutical composition containing the liposome recited in ~~claim 2~~ claim 1.

6. (previously presented) The pharmaceutical composition according to claim 5, wherein the composition is in an injection form.

7. (currently amended) A method for treatment of cancer, which comprises administering a pharmaceutical composition comprising a liposome to which a polyalkylene glycol and a genetically recombined wild type human serum albumin are bonded and in which an

antitumor agent is contained.

8. (currently amended) A method of extending the in vivo retention time of a ~~physiologically~~ pharmaceutically active ingredient contained in a liposome comprising binding the liposome to a polyalkylene glycol and a genetically recombined wild type human serum albumin.

9. (previously presented) A process for the production of the liposome comprising a step selected from the group consisting of (A), (B), (C), (D), (E) and (F):[[,]]

(A) bonding a liposome containing a compound represented by the following formula (1):



(1)

(wherein R is an acyl group derived from a fatty acid having 2 to 35 carbon atoms) and 1,2-distearol-*sn*-glycero-3-phosphoethanolamine bonded to a polyalkylene glycol (PEG-DSPE) as constituent lipids to wild type human serum albumin;

(B) bonding a liposome containing a compound represented by the following formula (2):



(2)

(wherein R has the same meaning as defined above) and 1,2-distearol-*sn*-glycero-3-phosphoethanolamine bonded to a polyalkylene glycol (PEG-DSPE) as constituent lipids to a compound represented by the formula (3):

$$(Alb\text{-}NH)\text{-}CO\text{-}CH_2\text{-}CH_2\text{-}SH \qquad (3)$$

(wherein Alb-NH is a group formed by removing one hydrogen atom of the amino group from a wild type human serum albumin molecule represented by Alb-NH_2);

(C) bonding a liposome containing a compound represented by

the following formula (4):



(4)

(wherein n is an integer of 5 to 100,000 and R has the same meaning as defined above) as a constituent lipid is bonded to a compound represented by the formula (5):

$$(Alb\text{-}NH)\text{-}CO\text{-}CH_2\text{-}SH \qquad (5)$$

(wherein Alb-NH has the same meaning as defined above);

(D) incorporating a compound represented by the following formula (6):



(6)

(wherein n, R and Alb-NH have each the same meaning as defined above) into a liposome;

(E) bonding a liposome containing the compound represented by the above formula (1) as a constituent lipid to a compound represented by the following formula (7):



(7)

(wherein -NH-Alb-NH_2 is a group formed by removing one hydrogen atom from one of the amino groups of an albumin molecule represented by H_2N-Alb-NH_2, and n has the same meaning as defined above); or

(F) bonding a liposome containing the compound represented by the above formula (2) as a constituent lipid to a compound represented by the following formula (8):



(8)

(wherein -NH-Alb-NH- is a group formed by removing one hydrogen atom from each of the two amino groups of an albumin molecule represented by the formula H_2N-Alb-NH_2, and n has the same meaning as defined above).

10. (currently amended) A pharmaceutical composition containing the liposome mentioned in ~~claim 3~~ claim 1.

11. (previously presented) A pharmaceutical composition containing the liposome mentioned in claim 4.

12. (previously presented) The pharmaceutical composition according to claim 10, wherein the composition is in an injection form.

13. (previously presented) The pharmaceutical composition according to claim 11, wherein the composition is in an injection form.

14 - 16. (canceled)

17. (new) The method according to claim 9, wherein the wild type human serum is prepared by a recombinant gene technique.